ILMN - Stock Analysis & Overview

About Illumina, Inc.

Medical - Diagnostics & Research

Healthcare

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services...

Illumina, Inc. Key Metrics

Market Cap: $21B
52 Weeks Low: $86.58
52 Weeks High: $144.15
P/B: 14.50x
P/E: -6.84x
P/S: 4.71x

Upcoming Events

ILMN Analyst Forecasts

‌

ILMN Financials

ILMN Income Statement Key Metrics

Revenue(TTM)4.43 B
Gross Profit(TTM)2.75 B
EBITDA(TTM)1.57 B
Net Income(TTM)-3.04 B
EPS Diluted(TTM)-19.169999999999998

Decode ILMN's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

ILMN earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of ILMN (0.611) is higher than the average of its peers (0.536).

Net Profit Margin vs Peers

Net profit margin ratio of ILMN (-0.258) is lower than the average of its peers (-0.114).

ILMN Return on Equity

See how efficiently ILMN generates profit for it's shareholders.

-20.21%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of ILMN (-0.202) is lower than the average of its peers (-0.015).

Return on Equity Growth

ILMN's Return on Equity has shown poor growth over the past 10 years, increasing by only 1.77%.

ILMN Revenue Growth

See how ILMN has grown it's revenue over the past 10 years.

‌

Revenue Growth

ILMN's revenue has grown modestly over the past 10 years, increasing by over 9.24%.

Illumina, Inc.

Page title

Section title